MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

14.66 -5.36

Overview

Share price change

24h

Current

Min

14.46

Max

15.71

Key metrics

By Trading Economics

Income

-14M

-25M

Sales

-5.5M

66M

Profit margin

-38.059

Employees

342

EBITDA

-14M

-19M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+37.53% upside

Dividends

By Dow Jones

Next Earnings

13 Aug 2025

Market Stats

By TradingEconomics

Market Cap

79M

1.9B

Previous open

20.02

Previous close

14.66

News Sentiment

By Acuity

63%

37%

324 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

18 Jul 2025, 21:01 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 Jul 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 Jul 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 Jul 2025, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 Jul 2025, 20:46 UTC

Earnings

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 Jul 2025, 20:39 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 Jul 2025, 20:36 UTC

Earnings

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 Jul 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 Jul 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Jul 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 Jul 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 Jul 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 Jul 2025, 18:24 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 Jul 2025, 18:19 UTC

Earnings

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 Jul 2025, 18:11 UTC

Acquisitions, Mergers, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 Jul 2025, 18:11 UTC

Earnings

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 Jul 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 Jul 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 Jul 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 Jul 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Jul 2025, 16:04 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 Jul 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 Jul 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 Jul 2025, 15:47 UTC

Market Talk
Earnings

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

37.53% upside

12 Months Forecast

Average 21.29 USD  37.53%

High 29 USD

Low 19 USD

Based on 7 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

12.42 / 14.93Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

324 / 376 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.